hamartoma-tumor syndrome . Arch Dermatol 2006 ; 142 : 625 – 632 . 28. Jazaeri AA Lu K Schmandt R . Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma . Mol Carcinog 2003 ; 36 : 53 – 59 . 29
Search Results
Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, and Rashmi Kumar
Tomas G. Lyons and Mark E. Robson
. 13. Gelmon KA Tischkowitz M Mackay H . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study . Lancet Oncol
Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman
epithelial ovarian carcinoma—a cost-effectiveness analysis . Int J Gynecol Cancer 2007 ; 17 : 1019 – 1024 . 38. Fust K Li X Maschio M . Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent
Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel
Yap TA . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers . N Engl J Med 2009 ; 361 : 1 – 12 . 12. Lynch HT Casey MJ Snyder CL . Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology
Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk
is a monoclonal antibody directed against VEGF-A. It was the first clinically available antiangiogenic agent in the United States 19 and has been successfully studied in many solid tumors, including colon, lung, breast, renal, brain, and ovarian
Alok A. Khorana
-bearing microparticles are associated with venous thromboembolic events in malignancy . Clin Cancer Res 2009 ; 15 : 6830 - 6840 . 24 Han LY Landen CN Jr Kamat AA . Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian
Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland
broad-spectrum mass spectrometry genotyping . J Mol Diagn 2011 ; 13 : 64 – 73 . 35. Kabiawu Ajise OE Feldstein JT Soslow R . Assessment of BRAF V600E mutation status by immunohistochemistry in lung and ovarian carcinomas [abstract] . Mod
Lois Ramondetta
. Thaker PH Han LY Kamat AA . Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma . Nat Med 2006 ; 12 : 939 – 944 . 55. Wong HP Yu L Lam EK . Nicotine promotes colon tumor growth and angiogenesis
Mary B. Daly, Robert Pilarski, Michael Berry, Saundra S. Buys, Meagan Farmer, Susan Friedman, Judy E. Garber, Noah D. Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Shaveta Vinayak, Nicoleta C. Voian, Jeffrey N. Weitzel, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, and Susan Darlow
epidemiology study . J Natl Cancer Inst 2010 ; 102 : 475 – 483 . 16. Norquist BM Harrell MI Brady MF . Inherited mutations in women with ovarian carcinoma . JAMA Oncol 2015 ; 2 : 1 – 9 . 17. Ramus SJ Song H Dicks E . Germline
Neelima Vidula, Leif W. Ellisen, and Aditya Bardia
cancer. Presented at ESMO Congress 2019; September 27–October 1, 2019; Barcelona, Spain. 19. Oza AM , Tinker AV , Oaknin A , . Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a
